SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
65.94
+0.52 (+0.79%)
As of 10:57AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close65.42
Open65.10
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range65.10 - 65.96
52 Week Range25.38 - 87.65
Volume553,948
Avg. Volume7,417
Market Cap82.262B
Beta0.84
PE Ratio (TTM)9.91
EPS (TTM)6.66
Earnings DateApr 27, 2018
Forward Dividend & Yield3.03 (4.59%)
Ex-Dividend Date2018-05-11
1y Target Est79.15
  • Sanofi in talks to sell generics arm for $2.4 bln
    Reuters Videos8 days ago

    Sanofi in talks to sell generics arm for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.

  • Reuters32 minutes ago

    Boehringer's operating income up 20.7 percent on Sanofi deal

    Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros (3.06 billion pounds) last year, boosted by the purchase of Sanofi's (SASY.PA) veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis (ZTS.N). In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.

  • Reuters43 minutes ago

    Boehringer's operating income up 20.7 percent on Sanofi deal

    Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis. In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.

  • Reutersyesterday

    UK bans Sanofi epilepsy drug without pregnancy prevention plan

    A Sanofi (SASY.PA) drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme. The move follows a scandal over the lack of information given to patients about the risks associated with valproate, which was first approved in France in 1967 and remains a widely used treatment for epilepsy. It is sold by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders.

  • Sanofi (EPA:SAN): Immense Growth Potential?
    Simply Wall St.yesterday

    Sanofi (EPA:SAN): Immense Growth Potential?

    Sanofi’s (ENXTPA:SAN) latest earnings announcement in December 2017 showed that the business experienced a significant headwind with earnings declining by -13.74%. Today I want to provide a brief commentary onRead More...

  • GlobeNewswireyesterday

    Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

    Paris - 24th April 2018   -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

  • GlobeNewswireyesterday

    Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

    Paris - 24th April 2018  -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

  • Motley Fool5 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Reuters6 days ago

    WHO recommends testing before use of Sanofi's dengue vaccine

    The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks6 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Reuters8 days ago

    Sanofi's CFO Contamine to retire later this year

    PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...

  • Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
    Bloomberg8 days ago

    Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

    Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

  • The Wall Street Journal8 days ago

    [$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion

    The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.

  • In Pharma, If You Can't Join Them, Beat Them
    Bloomberg8 days ago

    In Pharma, If You Can't Join Them, Beat Them

    Advent is preparing to take on a drugmaker it tried and failed to buy.

  • Reuters8 days ago

    Bank trio expected to lead financing on Zentiva sale

    Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.

  • Reuters8 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 billion

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Reuters8 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Financial Times8 days ago

    [$$] Advent in exclusive talks to buy Sanofi generics business

    Private equity firm Advent has confirmed that it has entered into exclusive negotiations to buy Zentiva, Sanofi’s European generics business, for €1.91bn. A statement from the two firms on Tuesday said ...

  • The Wall Street Journal8 days ago

    [$$] Sanofi in Talks With Advent to Sell Zentiva

    Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.

  • Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
    Bloomberg8 days ago

    Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech

    Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...

  • GlobeNewswire8 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi`s European generics business Advent to invest in Zentiva to ...

  • GlobeNewswire8 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

    Divestiture of European generics, a non-core business, is part of Sanofi's strategy to simplify and reshape the Company. Transaction anticipated before end of the year, following consultation with Sanofi employees' representatives and subject to customary closing conditions.

  • The Wall Street Journal9 days ago

    [$$] Charterhouse Portfolio Company Closes Sanofi Deal

    Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.

  • Reuters9 days ago

    France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

    French healthcare and drugs group Sanofi (SASY.PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday. Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio. Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.

  • Reuters9 days ago

    PRESS DIGEST- Financial Times - April 16

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Barclays creates venture capital-style unit https://on.ft.com/2qCe467 ...